ASX:IMM Immutep (IMM) Stock Price, News & Analysis → Watch this FREE trading tutorial while it’s still available (From InvestorPlace) (Ad) Free IMM Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2.15 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield6.41%Price TargetN/A Stock AnalysisStock Analysis Get Immutep alerts: Email Address Ad Allegiance GoldCould Your Accounts Be Frozen?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit About Immutep Stock (ASX:IMM)Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Read More Ad Allegiance GoldCould Your Accounts Be Frozen?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit IMM Stock News HeadlinesMay 2, 2024 | finance.yahoo.comPositive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue SarcomaApril 26, 2024 | msn.comTesla Stock Is Ripping Higher Wednesday: What's Going On?May 4, 2024 | Stansberry Research (Ad)BUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).April 26, 2024 | msn.comMeta stock tanks as aggressive AI spending worries Wall StreetApril 24, 2024 | marketwatch.comImmutep Shares Rise 12% After Positive Data From Eftilagimod TrialApril 24, 2024 | finance.yahoo.comWhy Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?April 24, 2024 | msn.comMarket Highlights: Tesla surges after Q1 update, iron ore slumps, and 5 ASX small caps to watch todayApril 24, 2024 | msn.comWhy Argosy Minerals, Immutep, Pointsbet, and Regis Resources shares are racing higherMay 4, 2024 | Stansberry Research (Ad)BUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).April 17, 2024 | finance.yahoo.comImmutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerApril 4, 2024 | markets.businessinsider.comImmutep Ltd (PRRUF) Gets a Buy from Bell PotterMarch 28, 2024 | msn.comPrincess Banton-Lofters Sobs After Missing Chance to 'Say Goodbye' to Her Dad Before His Death (Exclusive)March 7, 2024 | markets.businessinsider.comAnalyst Issues Buy Rating on Immutep Stock Amid Promising Efti Drug Trial ResultsMarch 5, 2024 | finance.yahoo.comImmutep Announces First Clinical Data from 90mg Dosing of EftiFebruary 29, 2024 | finance.yahoo.comIndividual investors account for 60% of Immutep Limited's (ASX:IMM) ownership, while institutions account for 29%February 22, 2024 | benzinga.comImmutep Stock (NASDAQ:IMMP) Insider TradesJanuary 30, 2024 | finance.yahoo.comImmutep Quarterly Activities Report Q2 FY24January 14, 2024 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Immutep Ltd (PRRUF)January 9, 2024 | morningstar.comImmutep Ltd ADR YP1ADecember 30, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Immutep Ltd (PRRUF)December 21, 2023 | markets.businessinsider.comImmutep Receives Regulatory Feedback On TACTI-004 Trial In Metastatic NSC Lung CancerDecember 21, 2023 | finance.yahoo.comImmutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerDecember 16, 2023 | benzinga.comImmutep Stock (NASDAQ:IMMP) Dividends: History, Yield and DatesDecember 7, 2023 | msn.comImmutep receives A$2.6M R&D tax incentive from French GovernmentDecember 7, 2023 | finance.yahoo.comImmutep Receives A$2.6 million R&D Tax Incentive from French GovernmentNovember 27, 2023 | finance.yahoo.comImmutep (ASX:IMM) investors are sitting on a loss of 22% if they invested five years agoNovember 23, 2023 | uk.finance.yahoo.comImmutep Limited (IMMP) stock price, news, quote & history – Yahoo FinanceSee More Headlines Receive IMM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2019Today5/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:IMM CUSIPN/A CIKN/A Webwww.primabiomed.com.au Phone61 2 8315 7003FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-5.92Net Income$-40,500,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.12% Return on Assets-25.70% Debt Debt-to-Equity Ratio1.40 Current Ratio17.24 Quick Ratio13.78 Sales & Book Value Annual Sales$3.93 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.83 Book ValueA$0.10 per share Price / BookN/AMiscellaneous Outstanding Shares1,190,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.83 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Marc Voigt (Age 51)CEO, MD, CFO, Chief Business Officer & Executive Director Comp: $565.12kMs. Deanne Miller LLB (Age 47)COO, General Counsel & Joint Company Secretary Comp: $369.56kDr. Frederic Triebel M.D. (Age 69)Ph.D., Chief Scientific Officer & Executive Director Comp: $451.12kMr. Christian Mueller BBAMSc., Senior Vice President of Regulatory & StrategyMr. Florian D. Vogl M.D.M.Sc., Ph.D., Chief Medical OfficerMs. Indira NaiduJoint Company SecretaryMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersLis (Elisabeth) BoyceSold 589,955 sharesTotal: $174,036.73 ($0.30/share)Pete MeyersSold 500,000 sharesTotal: $142,500.00 ($0.29/share) IMM Stock Analysis - Frequently Asked Questions How were Immutep's earnings last quarter? Immutep Limited (ASX:IMM) released its quarterly earnings data on Wednesday, February, 27th. The company reported $0.00 EPS for the quarter. What other stocks do shareholders of Immutep own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include ICL Group (ICL), Geron (GERN), Immersion (IMMR), Innovative Industrial Properties (IIPR), Evoke Pharma (EVOK), Enphase Energy (ENPH), DURECT (DRRX), Denali Therapeutics (DNLI), Cynata Therapeutics (CYP) and Yamana Gold (AUY). This page (ASX:IMM) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingJeff Bezos Just Humiliated Elon MuskInvestorPlaceForget Nvidia. This is the future of AIPorter & CompanyThe asset beating inflation by 4xColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.